Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

episode

Urology Times Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

9/24/26: Trump Backs Diesel Export Ban, Latinos Flee GOP, Iran Lashes Out At Israel 1h 11m · 24 Sep 2026 · Breaking Points with Krystal and Saagar

2026-09-24- KSR - Hour 1 1h 4m · 24 Sep 2026 · KSR

Football vs jetlag | Who is the Mayo of the NFL? | Super Bowl favourites | Hockey's coaching scandal | US Sports Roundtable 1h 11m · 24 Sep 2026 · Indo Sport

Jason Sudeikis: JUCO Hoops, SNL & Why Apple Bet on Ted Lasso 1h 24m · 24 Sep 2026 · All The Smoke

Is This The October Surprise? (Ep. 2602) 1h 30m · 24 Sep 2026 · The Dan Bongino Show

Sage Advice From Granny Bingo 19 min · 24 Sep 2026 · It's A Lot with Abbie Chatfield

Report any issue

Source

Recorded22 Jun 2023

Publisheraudioboom.com ↗

Handlerec:11143569

Show notes

In this episode, David M. Schuster, MD, FACR, highlights the recent FDA approval of flotufolastat F 18 (POSLUMA), a PSMA-PET imaging agent in prostate cancer. Schuster is a professor of radiology and imaging sciences and the director of the division of nuclear medicine and molecular imaging at Emory University School of Medicine in Atlanta, Georgia.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in